<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579679</url>
  </required_header>
  <id_info>
    <org_study_id>2020-012-00EU1</org_study_id>
    <nct_id>NCT04579679</nct_id>
  </id_info>
  <brief_title>Open-Label Surufatinib in European Patients With NET</brief_title>
  <official_title>An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to&#xD;
      intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low- to&#xD;
      intermediate-grade (Grade 1 or Grade 2), well-differentiated NETs.&#xD;
&#xD;
      The study will enroll 4 cohorts of varying NETs, as follows:&#xD;
&#xD;
        -  Cohort A - NET of lung origin&#xD;
&#xD;
        -  Cohort B - NET of small bowel origin&#xD;
&#xD;
        -  Cohort C - NET of non-small bowel, non-pancreas, and non-lung origin&#xD;
&#xD;
        -  Cohort D - NET of any origin (DDI substudy)&#xD;
&#xD;
      All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days&#xD;
      starting on Cycle 1 Day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Disease control rate the incidence of complete response, partial response and stable disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentrations of surufatinib with blood sampling</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Blood sampling will be taken to measure levels of the study drug in all cohorts and cytochrome P450 in cohort D only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc change from Baseline</measure>
    <time_frame>up to 6 months</time_frame>
    <description>QTc change from baseline in approximately first 40 patients (Cohorts A, B, and C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety and tolerability of surufatinib</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluate the safety and tolerability of surufatinib in patients with NET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>the duration between the enrollment date and the first disease progression (PD) or death (whichever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Neuroendocrine Tumours</condition>
  <condition>Neuroendocrine Tumour of the Lung</condition>
  <condition>Small Intestinal NET</condition>
  <arm_group>
    <arm_group_label>Surufatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1&#xD;
Cohort D:&#xD;
Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Surufatinib 300 mg oral once daily</description>
    <arm_group_label>Surufatinib</arm_group_label>
    <other_name>HMPL-012, sulfatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Has histologically or cytologically documented, locally advanced, or metastatic NET&#xD;
             and has progressed on at least 1 prior line of therapy, but no more than 3 therapies;&#xD;
&#xD;
          2. Has radiologic evidence of progressive tumour within 12 months of study enrolment&#xD;
&#xD;
          3. Is willing and able to provide informed consent&#xD;
&#xD;
          4. Is ≥18 years of age&#xD;
&#xD;
          5. Has measurable lesions according to RECIST Version 1.1&#xD;
&#xD;
          6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential agree to use a highly effective form(s) of contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade&#xD;
             1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum&#xD;
             chemotherapy&#xD;
&#xD;
          2. Major surgery within previous 4 weeks or radiation therapy within 2 weeks prior to the&#xD;
             start of treatment.&#xD;
&#xD;
          3. Prior VEGF/VEGFR-targeted therapy&#xD;
&#xD;
          4. Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or&#xD;
             diastolic blood pressure ≥90 mmHg, despite antihypertensive medication&#xD;
&#xD;
          5. Gastrointestinal disease or condition within 6 months prior to first dose&#xD;
&#xD;
          6. Has a history or presence of a serious haemorrhage (&gt;30 mL within 3 months) or&#xD;
             haemoptysis (&gt;5 mL blood within 4 weeks) within 6 months of first dose of study drug.&#xD;
&#xD;
          7. Clinically significant cardiovascular disease.&#xD;
&#xD;
          8. Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days&#xD;
             or longer; patients requiring steroids within 4 weeks prior to start of study&#xD;
             treatment will be excluded.&#xD;
&#xD;
          9. A high risk of bleeding at screening due to tumour invasion into major vessels, such&#xD;
             as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined&#xD;
             by investigators.&#xD;
&#xD;
         10. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first&#xD;
             dosing, or thromboembolic events (including stroke and/or transient ischaemic attack)&#xD;
             within 12 months.&#xD;
&#xD;
         11. Has a clinically meaningful ongoing infection (eg, requiring intravenous treatment&#xD;
             with anti-infective therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Study Director</role>
    <affiliation>HUTCHMED</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick Lawn</last_name>
    <phone>+44 7826 422448</phone>
    <email>nickl@hutch-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Smith</last_name>
      <phone>0033 556 795 808</phone>
      <email>denis.smith@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien Hadoux</last_name>
      <phone>33-0142116361</phone>
      <email>julien.hadoux@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Hadoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henning Jann</last_name>
      <email>henning.jann@charite.de</email>
    </contact>
    <investigator>
      <last_name>Henning Jann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Pavel</last_name>
      <phone>49-9131 85-34651</phone>
      <email>marianne.pavel@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Marianne Pavel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen, Klinik fur Endokrinologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harald Lahner</last_name>
      <phone>49-201-723</phone>
      <email>harald.lahner@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Harald Lahner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Cives</last_name>
      <phone>0039 080 338 9098</phone>
      <email>mauro.cives@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Mauro Cives</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST-Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Berruti</last_name>
      <phone>39-030-3996536</phone>
      <email>alfredo.berruti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alfredo Berruti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi (AOUC)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Antonuzzo</last_name>
      <phone>39 0557947298</phone>
      <email>lorenzo.antonuzzo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Antonuzzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Spada</last_name>
      <phone>0039 025 748 9599</phone>
      <email>francesca.spada@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Spada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halfdan Sorbye</last_name>
      <phone>0047-55973589</phone>
      <email>halfdan.sorbye@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Halfdan Sorbye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Espen Thiis-Evensen</last_name>
      <email>ethiisev@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Espen Thiis-Evensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologis (ICO) - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>8013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Carlos Ruffinelli Rodriguez</last_name>
      <phone>34932607744</phone>
      <email>jruffinelli@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Jose Carlos Ruffinelli Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Capdevila</last_name>
      <phone>34-93-4894350</phone>
      <email>jcapdevila@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Jaume Capdevila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Alonso Gordoa</last_name>
      <phone>34-91-336-8263</phone>
      <email>talonso@oncologiahrc.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Alonso Gordoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Garcia Carbonero</last_name>
      <phone>34-91-390 80 00</phone>
      <email>rgcarbonero@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rocio Garcia Carbonero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Benavent</last_name>
      <phone>0034 955 013 068</phone>
      <email>martabenaventv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Benavent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Krell</last_name>
      <email>daniel.krell@hcahealthcare.co.uk</email>
    </contact>
    <investigator>
      <last_name>Daniel Krell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Valle</last_name>
      <phone>44-161-446 8106</phone>
      <email>juan.valle@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Juan Valle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

